Targeting PD-L1 on tumor cells
AssigneeMayo Foundation for Medical Education and Research
InventorsStephen James Russell, Autumn J. Schulze, Arun Ammayappan, Kah-Whye Peng, Camilo Ayala Breton
Life of this patent
Estimating the term…
Abstract
This document relates to materials and methods for treating cancer. For example, this document provides materials and methods for using PD-L1 targeting domains in bispecific chimeric polypeptides, chimeric transmembrane polypeptides, genetically modified viruses, nucleic acid vectors, and/or fusion-inducing cells to treat cancer.
Claims5
A nucleic acid encoding a chimeric transmembrane polypeptide, wherein said chimeric transmembrane polypeptide is a chimeric antigen receptor comprising (a) a PD-L1 targeting domain and (b) an intracellular costimulatory signaling domain, wherein said PD-L1 targeting domain comprises an antibody single-chain variable fragment comprising an amino acid sequence encoded by a nucleotide sequence having at least 90% identity to the nucleotide sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.